Stockreport

Cellect Announces Positive Phase I/II Mid-Study Results of Its ApoGraft™ Technology

Cellect Biotechnology Ltd. - American Depositary Shares  (APOP) 
US:NASDAQ Investor Relations: cellect.co
PDF TEL AVIV, Israel, March 27, 2019 /PRNewswire/ -- Further validating its ApoGraft™ technology, Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell [Read more]